About us

We are united behind a new approach to personalized immunotherapy

Our expert leadership team draws on many decades of experience in complementary areas of biopharma development and commercialization, which they bring to bear on Imvax’s strategy to deliver a portfolio of therapies targeting solid tumors.

Meet our leadership team

john furey

John P. Furey

Chief Executive Officer

david andrews

David W. Andrews, M.D.

Co-Founder, Chief Medical Officer

mark exley

Mark A. Exley, Ph.D.

Chief Scientific Officer

sean hemingway

Sean P. Hemingway, M.S.

Chief Operating Officer

john limongelli

John M. Limongelli

Chief Legal Officer

josh muntner

Josh Muntner, MBA

Chief Financial Officer

peter corr

Peter B. Corr, Ph.D.

Co-Founder, Chairman of the Board

steven altschuler

Steven M. Altschuler, M.D.

Ziff Capital Partners

david andrews

David W. Andrews, M.D.

Co-Founder, Chief Medical Officer

david bunning

David G. Bunning

TLP Investment Partners LLC

iran brind

Ira Brind, J.D.

President, Brind Investments, Inc.

wendy dicicco

Wendy DiCicco

Board Advantage, LLC

john furey

John P. Furey

Chief Executive Officer

thomas pfisterer

Thomas Pfisterer

Wild Group Management AG

ted-koutouzis__69066

Ted Koutouzis, M.D.

Fiscus Ventures & Reimagined Ventures

shefali agarwal

Shefali Agarwal

Epizyme

tyler curiel

Tyler Curiel

UT Health San Antonio